Cart
sales@molnova.com
Tyrphostin A1
CAS No. 2826-26-8
Tyrphostin A1( Tyrphostin 1 | AG9 )
Catalog No. M20945 CAS No. 2826-26-8
Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 50 | In Stock |
|
| 50MG | 71 | In Stock |
|
| 100MG | 91 | In Stock |
|
| 200MG | 133 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTyrphostin A1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
In Vitro——
-
In Vivo——
-
SynonymsTyrphostin 1 | AG9
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2826-26-8
-
Formula Weight184.19
-
Molecular FormulaC11H8N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (542.92 mM)
-
SMILESCOc1ccc(C=C(C#N)C#N)cc1
-
Chemical Name2-[(4-Methoxyphenyl)methylidene]propanedinitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Du C Bright J J Sriram S . Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice[J]. Journal of Neuroimmunology 2001 114(1-2):69-79.
molnova catalog
related products
-
7,8-Dihydroxyflavone
7, 8-Dihydroxyflavone (7, 8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.
-
PD-161570
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
